Journalists learned from the National Medical Insurance Bureau on the 2nd that the on-site negotiations for the adjustment of the national medical insurance pharmaceutical catalogue for 2024 have recently concluded smoothly. The new version of the medical insurance pharmaceutical catalogue, after expansion, is expected to be officially released to the public at the end of November and implemented on January 1st next year. A spokesperson from the Medical Service Management Department of the National Medical Insurance Bureau told reporters that from October 27th to the 30th at noon, the National Medical Insurance Bureau organized on-site negotiations and bidding with 25 negotiation experts from medical insurance departments of various provinces across the country and related pharmaceutical companies. This involved a total of 127 companies and 162 types of drugs, including 117 drugs outside the medical insurance catalogue and 45 renegotiated drugs within the catalogue. The companies participating in this year's negotiations include foreign companies such as Novartis, Sanofi, as well as domestic enterprises like Jiangsu Hengrui Medicine, and Xinda. There are also large multinational companies like Roche, Johnson & Johnson, as well as emerging biomedical companies like Kangfang and Yunding Xinyao. In addition, there are state-owned enterprises like China Resources, as well as private enterprises like Qilu Pharmaceutical and Yangtze River Pharmaceutical. (Xinhua News Agency)